Evidence map›Paper›PMID 38388989›Full record

ArticleCell biochemistry and biophysics2024

Anti-inflammatory effects of α-humulene on the release of pro-inflammatory cytokines in lipopolysaccharide-induced THP-1 cells.

Lucas Becker, Dirk Holtmann

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Cell biochemistry and biophysics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06842316 (In Vitro Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06842316 recruitingnot on this mapstarted 2025, after this paper: background citation

In Vitro Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases

TypeobservationalSponsorCentre Hospitalier Régional d'OrléansRan2025 to 2027Enrolled100ConditionsInflammatory Disorder of Immune System, Spondylitis, Ankylosing, Arthritis, Rheumatoid, Arthritis, PsoriaticArms1 blood sample, 40 mL (collection during a blood test, part of the standard of care for this disease)
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lucas BeckerBioprocess Intensification, Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Wiesenstrasse 14, 35390, Giessen, Germany.
Dirk HoltmannBioprocess Intensification, Institute of Bioprocess Engineering and Pharmaceutical Technology, University of Applied Sciences Mittelhessen, Wiesenstrasse 14, 35390, Giessen, Germany. dirk.holtmann@kit.edu.
Technische Hochschule Mittelhessen · DE

Funding

Bundesministerium für Bildung und Forschung 01B1050A
6 · The paper itself

Abstract

While acute inflammation is an essential physical response to harmful external influences, the transition to chronic inflammation is problematic and associated with the development and worsening of many deadly diseases. Until now, established pharmaceutical agents have had many side effects when used for long periods. In this study, a possible anti-inflammatory effect of the sesquiterpene α-humulene on lipopolysaccharide (LPS) induction was tested. Herein, human THP-1-derived macrophages were used and their pro-inflammatory interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin-1β (IL-1β) cytokine release was measured by means of enzyme-linked immunosorbent assay. A dose-dependent effect of α-humulene on IL-6 release was observed at 0.5 and 100 µM α-humulene, with a maximum IL-6 inhibition of 60% compared to the LPS reference value after the addition of 100 µM α-humulene. TNF-α as well as IL-1β cytokine concentrations were not reduced by the addition of 0.5 and 100 µM α-humulene. This study suggests that α-humulene has potential as a promising natural alternative to established pharmaceuticals for the treatment of elevated IL-6 levels and chronic inflammation in humans.

Indexed as

Anti-Inflammatory AgentsCytokinesInterleukin-1betaInterleukin-6LipopolysaccharidesMonocyclic SesquiterpenesTumor Necrosis Factor-alphaHumansMacrophagesSesquiterpenesTHP-1 CellsAnti-Inflammatory AgentsCytokineshumuleneInterleukin-1betaInterleukin-6LipopolysaccharidesMonocyclic SesquiterpenesSesquiterpenesTumor Necrosis Factor-alphaAnti-inflammatoryCytokinesInflammationLipopolysaccharidesTHP-1 cellsα-humulene

Identifiers

PMID38388989
PMCPMC11344727
OpenAlexW4392029490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.